https://www.bioworld.com/rss en-us The U.S. SEC reached a settlement with Weiguo Zhai resolving insider trading charges related to Astrazeneca plc’s $1.1 billion acquisition of Icosavax Inc. in 2023. http://www.bioworld.com/articles/732534 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732534-former-astrazeneca-employee-settles-insider-trading-charges Of all the U.S. SEC’s recent proposed rules to make going, and staying, public more attractive, perhaps the most beneficial for biopharma and med-tech startups is the amendment that would give public companies the flexibility to file semi-annual rather than quarterly reports, Ben Bradford, head of external affairs at Massbio, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/732433 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732433-sec-reform-good-for-life-sciences-startups-but-getting-pushback Gears with regulatory words As of May 21, the U.S. SEC’s “no-deny” settlement policy is dead. For the past 50 years, the agency has required settling defendants to sign an agreement stating that they neither admit nor deny the SEC’s allegations. And beyond that, the standard settlement prohibits, under threat of court action, the defendants from ever denying the allegations publicly. According to an SEC notice to be published in the May 21 Federal Register, the agency has reconsidered the issue and is now rescinding the no-deny rule. Federal Register, the agency has reconsidered the issue and is now rescinding the no-deny rule.]]> http://www.bioworld.com/articles/731346 Wed, 20 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731346-sec-settlements-to-take-on-a-new-look-going-forward In a move aimed at incentivizing companies to go and stay public, the U.S. SEC proposed two rulemakings May 19 as a foundation to the agency’s Make IPOs Great Again agenda. http://www.bioworld.com/articles/731369 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731369-sec-looks-to-reforms-to-make-ipos-great-again The U.S. SEC filed a settlement April 29 that it reached with Anthony Cataldo regarding allegations that the former chairman and CEO of a clinical-stage biopharma company misappropriated about $3.2 million from the company and then concealed the misconduct from the company’s auditors. http://www.bioworld.com/articles/730830 Thu, 30 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730830-biopharma-exec-settles-with-sec-over-misappropriation-claims Another biopharma acquisition is at the heart of one of the U.S. SEC’s latest insider trading settlements. This time, the trading centered on Jazz Pharmaceuticals plc’s $935 million purchase of Chimerix Inc. last year. http://www.bioworld.com/articles/730487 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730487-former-jazz-employee-settles-insider-trading-charge Stryker Corp. revealed that the cyberattack which occurred last month had a material impact on its operations and will impact its financial results for the first quarter of 2026. However, the company said in an SEC filing that it is now fully operational and does not expect the incident to have a material impact on its 2026 full-year guidance. http://www.bioworld.com/articles/730224 Fri, 10 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730224-stryker-expects-cyberattack-to-impact-q1-results Cyber security padlock Stryker Corp. is scrambling to recover from a cyberattack that’s disrupting its global network and being claimed by pro-Iranian hackers. “At this time, there is no indication of malware or ransomware, and we believe the situation is contained to our internal Microsoft environment only,” the Kalamazoo, Mich.-based med-tech company said March 12. http://www.bioworld.com/articles/729479 Thu, 12 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729479-us-med-tech-company-begins-restoration-after-cyber-strike Red error exclamation point over binary code background The SEC filed civil charges against CBA Pharma Inc. and two top executives in U.S. district court, alleging they conducted a fraudulent securities offering that raised about $4.1 million from nearly 160 investors. http://www.bioworld.com/articles/728808 Tue, 10 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728808-pharma-company-execs-charged-with-securities-fraud Veradermics Inc. raised $256.3 million from an IPO on the New York Stock Exchange Feb. 4. The proceeds will fund three ongoing phase II/III clinical trials of VDPHL-01, its novel oral formulation of Rogaine (minoxidil) to treat pattern hair loss in men and women. http://www.bioworld.com/articles/728557 Wed, 04 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728557-hair-loss-drugmaker-veradermics-floats-upsized-256m-us-ipo Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, Calif.-based biopharma company would raise about $317.7 million. http://www.bioworld.com/articles/728477 Thu, 29 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728477-eikon-therapeutics-seeks-up-to-317m-raise-in-nasdaq-ipo Going public ticker Nader Pourhassan, the former president and CEO of Cytodyn Inc., was sentenced Jan. 23 to 30 months in prison for his role in a securities fraud scheme to deceive investors about the Vancouver, Wash.-based company’s development of leronlimab as a treatment for HIV and COVID-19. http://www.bioworld.com/articles/728505 Tue, 27 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728505-former-cytodyn-ceo-faces-prison-time-millions-in-restitution Another day, another insider trading settlement involving a biopharma company employee. This time the U.S. SEC settlement is with Mohit Verma, who was a researcher and associate director of immunology at the San Diego-based Infinitybio Inc. at the time of the alleged violative trading activity. http://www.bioworld.com/articles/728149 Thu, 22 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728149-put-options-put-biopharma-researcher-in-sec-hot-water Two former Spero Therapeutics Inc. executives are on the hook for a total of $187,500 in civil penalties in a settlement resolving U.S. SEC allegations of issuing misleading statements centered on the FDA’s evaluation of Spero’s lead drug candidate that resulted in a 64% stock drop in May 2022. http://www.bioworld.com/articles/728021 Tue, 20 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728021-misleading-statements-result-in-civil-penalties-for-spero-execs A biostatistician who was consulting for C4 Therapeutics Inc. is facing civil and criminal charges of U.S. securities fraud related to insider trading that allegedly produced nearly $500,000 in profit. http://www.bioworld.com/articles/727996 Thu, 15 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727996-biopharma-consultant-charged-with-insider-trading Advanced Biomed Inc. reported Dec. 30 the sale of its wholly owned Hong Kong subsidiary, Advanced Biomed (HK) Ltd., and related intellectual property to buyer Wei Ha Hui for $23,000. http://www.bioworld.com/articles/727303 Wed, 31 Dec 2025 11:00:00 -0500 https://www.bioworld.com/articles/727303-advanced-biomed-sells-hong-kong-subsidiary-for-23k Advanced Biomed’s A+Perfusc 3D cell culture system Advanced Biomed’s A+Perfusc 3D cell culture system Six individuals, including an investment banker, face multiple U.S. charges stemming from an alleged $41 million insider-trading scheme, plus stock manipulation schemes involving biopharma companies. The charges are related to three overlapping securities fraud schemes that occurred between June 2020 and February 2024. http://www.bioworld.com/articles/727356 Tue, 23 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727356-feds-break-up-alleged-stock-manipulation-ring-targeting-biopharma Pills, syringes, financial charts Pomdoctor Ltd. raised $20 million through a Nasdaq IPO on Oct. 8, with the funds geared to expand its mobile health platform for chronic diseases in China. http://www.bioworld.com/articles/724830 Fri, 10 Oct 2025 12:00:00 -0400 https://www.bioworld.com/articles/724830-pomdoctor-closes-20m-ipo-to-grow-mobile-health-platform-in-china Pomdoctor Pomdoctor With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, biopharma companies are building treasuries of digital assets to secure future R&D efforts and operational runways. Companies such as Artelo Biosciences Inc., MEI Pharma Inc., Windtree Therapeutics Inc. and 180 Life Sciences Corp. and have entered crypto deals in recent weeks, with the latter noting the potential to “unlock value outside traditional biotech milestones.” http://www.bioworld.com/articles/722935 Thu, 07 Aug 2025 11:00:00 -0400 https://www.bioworld.com/articles/722935-biopharmas-launch-new-crypto-financing-strategies Bitcoin surrounded by coins and financial charts, symbolizing cryptocurrency and digital investment Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price. http://www.bioworld.com/articles/721538 Tue, 24 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721538-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price. http://www.bioworld.com/articles/721456 Wed, 18 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721456-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering of 3.375 million shares at $4 per share. Hopewell, N.J.-based APUS is the second pharmaceutical company with Asian ties to float shares on the U.S. market this year. http://www.bioworld.com/articles/720492 Tue, 20 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/720492-apimeds-pharmaceuticals-raises-135m-from-nyse-american-debut Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering of 3.375 million shares at $4 per share. Hopewell, N.J.-based APUS is the second pharmaceutical company with Asian ties to float shares on the U.S. market this year. http://www.bioworld.com/articles/720119 Wed, 14 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/720119-apimeds-pharmaceuticals-raises-135m-from-nyse-american-debut The U.S. Securities and Exchange Commission said it obtained a judgment for a total of $17 million in penalties and disgorgement from a group of individuals and entities charged with investor fraud. http://www.bioworld.com/articles/719528 Wed, 30 Apr 2025 12:00:00 -0400 https://www.bioworld.com/articles/719528-sec-scores-17m-win-over-investor-fraud-allegations Gavel with whistle Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings. http://www.bioworld.com/articles/719777 Tue, 29 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/719777-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings China in red on globe Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings. http://www.bioworld.com/articles/719490 Thu, 24 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/719490-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings China in red on globe George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges. http://www.bioworld.com/articles/718080 Mon, 10 Mar 2025 12:00:00 -0400 https://www.bioworld.com/articles/718080-former-acadia-exec-pleads-guilty-to-insider-trading Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said. http://www.bioworld.com/articles/718015 Tue, 04 Mar 2025 11:00:00 -0500 https://www.bioworld.com/articles/718015-basel-medical-prices-88m-ipo Singapore Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said. http://www.bioworld.com/articles/717621 Thu, 27 Feb 2025 11:00:00 -0500 https://www.bioworld.com/articles/717621-basel-medical-prices-88m-ipo Singapore A former regional sales director at Lantheus Holdings Inc. is the latest biopharma official to settle insider trading charges with the U.S. SEC. As part of the settlement, John Heropoulos agreed to disgorge nearly $61,000, an equal amount in civil penalties and more than $10,000 in prejudgment interest, according to the SEC. http://www.bioworld.com/articles/716686 Tue, 28 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716686-insider-trades-on-sales-data-result-in-us-sec-settlement